are direct targets of the c-Jun transcription factor. Exposure to multiple chemotherapies further exploits this JNK-mediated axis to confer treatment resistance. Importantly, JNK inhibition or disruption of SPP1 or TNC expression sensitizes experimental mammary tumors and metastases to chemotherapy, thus providing insights to consider for future treatment strategies against metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Insua‐Rodríguez et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: